Published online Oct 24, 2023. doi: 10.5306/wjco.v14.i10.357
Peer-review started: July 19, 2023
First decision: August 24, 2023
Revised: September 6, 2023
Accepted: September 18, 2023
Article in press: September 18, 2023
Published online: October 24, 2023
Processing time: 96 Days and 20.1 Hours
Burkitt lymphoma (BL) is an exceptionally aggressive malignant neoplasm originating from either the germinal center or post-germinal center B cells. However, a standardized treatment regimen for BL has yet to be established. The utilization of microarray data and sequencing information retrieved from public databases presents promising prospects for the identification of novel diagnostic or therapeutic targets.
It is crucial to identify biomarkers that can predict the prognosis of BLs and distinguish patients who would benefit from specific therapies.
The aim of our study was to identify hub genes and conduct gene ontology analysis specifically in BL, as well as perform functional enrichment analysis. Additionally, we performed survival analysis and developed a novel prognostic model incorporating candidate genes along with clinical features.
The gene expression profiles and clinical traits of BL patients were obtained from the Gene Expression Omnibus database. Weighted gene co-expression network analysis (WGCNA) was employed to construct gene co-expression modules, while the cytoHubba tool was utilized to identify hub genes. Prognostic candidate genes were identified through overall survival (OS) analysis. A nomogram was developed to evaluate the predictive value of the hub genes.
In this study, we identified 8 modules through WGCNA analysis and found a significant correlation between the yellow module and age. By using the cytoHubba tool, we identified 10 hub genes (SRC, TLR4, CD40, STAT3, SELL, CXCL10, IL2RA, IL10RA, CCR7, and FCGR2B). Among these hubs, two genes (CXCL10 with P = 0.029 and IL2RA with P = 0.0066) were associated with OS based on our survival analysis.
This study is the first to investigate gene expression in BL using WGCNA. We have identified and validated 10 hub genes, demonstrating that the overexpression of CXCL10 and IL2RA in BL can serve as robust prognostic indicators. Furthermore, the integration of an mRNA signature with age nomogram holds promising potential for predicting patient outcomes in BLs.
Further genetic and experimental investigations are imperative to elucidate the underlying mechanism and functional significance of these hub genes in the carcinogenesis and progression of BLs.